{"article_title": "5 Lessons From FDA's First Biosimilar Review", "article_keywords": ["lessons", "week", "shed", "zarxio", "review", "sufficiently", "experts", "york", "weeks", "biosimilar", "fdas", "view"], "article_url": "http://www.law360.com/articles/608556/5-lessons-from-fda-s-first-biosimilar-review", "article_text": "5 Lessons From FDA's First Biosimilar Review\n\nLaw360, New York (January 8, 2015, 6:29 PM ET) -- Ringing endorsements by regulators and experts this week for Sandoz Inc.\u2019s biosimilar Zarxio offer key insights into how the U.S. Food and Drug Administration will oversee Big Pharma\u2019s next frontier, experts say.\n\n\n\nHere are five lessons from the first-of-its-kind review:\n\n\n\nClear Road to Approval Emerges\n\n\n\nThrough guidance and closed-door meetings with drugmakers, the FDA in recent years has shed light on the evidence needed to prove that a proposed biosimilar sufficiently copies an existing biologic. But this week\u2019s experience with Zarxio, the first product processed along...\n\nTo view the full article, register now.", "article_metadata": {"description": "Ringing endorsements by regulators and experts this week for Sandoz Inc.\u2019s biosimilar Zarxio offer key insights into how the U.S. Food and Drug Administration will oversee Big Pharma\u2019s next frontier, experts say. Here are five lessons from the first-of-its-kind review.", "csrf-token": "vyN2Q3x20Mt+ZhlGnKPJuq0Ou+JlJMe1/EwdO8Z2PvVQ8bk01MZWsaie9ZswOiH80YFL4t3sdsKS0+BDkojFow==", "og": {"url": "http://www.law360.com/articles/608556/5-lessons-from-fda-s-first-biosimilar-review", "image": "https://www.law360.com/images/360.png", "type": "website", "title": "5 Lessons From FDA's First Biosimilar Review - Law360"}, "csrf-param": "authenticity_token", "apple-itunes-app": "app-id=934560389, app-argument=law360://www.law360.com/articles/608556/5-lessons-from-fda-s-first-biosimilar-review", "viewport": "width=device-width, initial-scale=1.0"}, "_id": "\"57477af36914bd0286fd058e\"", "article_summary": "5 Lessons From FDA's First Biosimilar ReviewLaw360, New York (January 8, 2015, 6:29 PM ET) -- Ringing endorsements by regulators and experts this week for Sandoz Inc.\u2019s biosimilar Zarxio offer key insights into how the U.S. Food and Drug Administration will oversee Big Pharma\u2019s next frontier, experts say.\nBut this week\u2019s experience with Zarxio, the first product processed along...To view the full article, register now.\nHere are five lessons from the first-of-its-kind review:Clear Road to Approval EmergesThrough guidance and closed-door meetings with drugmakers, the FDA in recent years has shed light on the evidence needed to prove that a proposed biosimilar sufficiently copies an existing biologic."}